Current international consensus recommends comprehensive risk stratification for all patients based on serological markers: systematic testing for HBsAg, anti-HBc, and anti-HBs must be completed before treatment initiation to accurately identify the three risk groups—chronic infection, past infection, and susceptible populations (Schneider et al., 2025). This evidence concerns the gene KRT88P and infection.